A technique analogous to that used to generate DCs without a dedicated maturation step in many GBM vaccine clinical trials2,6,30,31 (M1) had low levels of CD83+ cells, as expected (20.7% ± 2.9%). The gene discussed is CD83; the disease is glioblastoma.